Keyphrases
Epidermal Growth Factor Receptor
100%
Resistant Cells
100%
Non-small Cell Lung Carcinoma Cells
100%
Carcinoma Cell Lines
100%
L858R/T790M
100%
Osimertinib
100%
Resistance Potential
37%
Non-small Cell Lung Cancer Patients
25%
Acquired Resistance
25%
Drug Resistance
25%
H1975
25%
Resistance Mechanisms
25%
Epithelial-to-mesenchymal Transition
25%
Autophagy Pathway
25%
Resistant Cell Lines
25%
Osimertinib Resistance
25%
T790M mutation
25%
Double mutation
12%
Third Generation
12%
Protein Expression
12%
Lung Cancer
12%
Transition Activity
12%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
12%
Epidermal Growth Factor Receptor Signaling
12%
High Efficacy
12%
Non-small Cell Lung Cancer (NSCLC)
12%
Western Blot
12%
Treatment Options
12%
Dilution Method
12%
Cell Viability Assay
12%
Cancer Mortality
12%
In Vitro Model
12%
Autophagy
12%
Protein Expression Analysis
12%
Growth Factor Receptor Tyrosine Kinase
12%
Receptor-independent
12%
Dose Escalation
12%
Druggable Targets
12%
Molecular Aberrations
12%
Mesenchymal Features
12%
Molecular Heterogeneity
12%
Total Cases
12%
Exon 19 Deletion
12%
L858R mutation
12%
Exon 19 Deletion mutation
12%
Tyrosine Kinase Domain
12%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Epidermal Growth Factor Receptor
100%
Osimertinib
100%
Drug Resistance
20%
Western Blot
10%
Lung Cancer
10%
Epidermal Growth Factor Receptor Kinase Inhibitor
10%
Cell Viability
10%
Cancer Mortality
10%
Viability Assay
10%
Biochemistry, Genetics and Molecular Biology
Epidermal Growth Factor Receptor
100%
Autophagy
42%
Exon
28%
Mesenchymal-Epithelial Transition
28%
Drug Resistance
28%
Protein Expression
28%
Dilution
14%
Western Blot
14%
Receptor Tyrosine Kinase Inhibitors
14%
Cancer Mortality
14%
Cell Viability
14%
Expression Analysis
14%